Zealand Pharma, Petrelintide, ZUPREME-1, Obesity, Overweight, Weight Management, Amylin Analog, Metabolic Health, EASD 2026, Phase 2, Phase 3, Chronic Weight Management,

COPENHAGEN, Denmark — September 30, 2026 Zealand Pharma announced additional data from the Phase 2 ZUPREME-1 trial of investigational...